Discover more
than you think
Developing innovative treatments in immuno-oncology, CNS and rare diseases
Proprietary
programs
We are advancing multiple first-in-class and best-in class programs.
Partnered programs
Name | Discovery | Candidate | Preclinical | Clinical | Partner |
---|---|---|---|---|---|
A2AR antagonist |
Preclinical
![]() |
||||
Multi-target collaboration for CNS |
Discovery
![]() |
||||
Multi-target collaboration for rare diseases |
Discovery
![]() |
Asset-centric
companies
Giving each program the best path forward
We create asset-centric vehicles for the development of our internal pipeline of preclinical candidates or to accelerate breakthrough innovations coming from academia. These asset-centric companies benefit from dedicated teams and targeted investments for a focused development.
Discovery
engine
We build a strong pipeline using our drug discovery platforms to tackle brand new targets, challenging or orphan GPCRs considered intractable targets.